Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Apixaban Market Heading Into 2029?

In recent times, the apixaban market has seen robust growth and it’s projected to further expand from $2.92 billion in 2024 to $3.16 billion in 2025, clocking a compound annual growth rate (CAGR) of 8.2%. This impressive growth during the historic period can be traced back to a surge in atrial fibrillation cases, an aging demographic, regulatory endorsements and expansion, promising clinical results, and a transition from warfarin to NOACs.

The apixaban market is projected to experience solid expansion in the coming years, with an anticipated valuation of “$4.31 billion by 2029, growing at a compound annual growth rate (CAGR) of 8.1%. This projected expansion during the forecast period is largely due to the ongoing prevalence of cardiovascular diseases, higher levels of awareness and diagnosis, growth in emerging markets, an elderly global populace, and modifications in health policies and reimbursement practices. The forecast period is also expected to see key trends such as the enhancement of drug delivery systems, an uptick in research and development activity, innovation and partnerships, apixaban’s approval by the FDA, and the rise of digital health and telemedicine.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=15979&type=smp

Which Factors Are Pushing The Apixaban Market Forward?

Growth in the apixaban market is anticipated due to the increasing occurrence of cardiovascular diseases. Such diseases include a variety of medical conditions affecting the heart and blood vessels such as coronary artery disease, stroke, and heart failure. Sedentary lifestyles, unhealthy eating habits, tobacco consumption, obesity, high blood pressure, diabetes, and an ageing demographic contribute to the escalating prevalence of these diseases. Apixaban plays a crucial role in the treatment of cardiovascular diseases by lowering the risk of blood clots, thereby preventing conditions like strokes, deep vein thrombosis, and pulmonary embolism. For example, in January 2024, the American Heart Association, a nonprofit organization based in the US, reported that deaths due to cardiovascular diseases reached 931,578, a slight increase of less than 3,000 fatalities from the 928,741 recorded in 2023. Given these circumstances, the upsurge in instances of cardiovascular diseases fuels the expansion of the apixaban market.

The apixaban market covered in this report is segmented –

1) By Dosage Form: Capsule, Tablets

2) By Application: Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)

3) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:

1) By Capsule: 2.5 mg Capsule, 5 mg Capsule

2) By Tablets: 2.5 mg Tablet, 5 mg Tablet

Which Trends Are Redefining The Future Landscape Of The Apixaban Industry?

Firms that dominate the apixaban market are concentrating their efforts on the creation of novel offerings, such as generic anticoagulant drugs, to bolster affordability and patient access. These endeavors also widen their market footprint while increasing competitiveness. A generic anticoagulant medicine works by obstructing various elements in the coagulation pathway, thereby lowering the chances of strokes and other heart-related events. For example, in October 2022, Tiefenbacher Pharmaceuticals, a health organization based in Germany, launched an off-brand version of Apixaban in Canada. This oral anticoagulant finds use in preventative measures after elective hip or knee replacements, as well as in averting strokes in cases of atrial fibrillation and in the treatment of deep vein thrombosis and pulmonary embolism, addressing a wide spectrum of clotting disorders. The organization developed 2.5 mg and 5 mg anticoagulant tablets at their labs in India. These are set to be distributed in Canada through collaborations with generic pharma firms and eventually launched in other international markets. Such a calculated approach results in substantial cost reductions for global healthcare systems and increases the availability of treatments that improve quality of life for many patients.

Which Organizations Are Driving Progress In The Apixaban Industry?

Major companies operating in the apixaban market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Group AG, Daiichi Sankyo Company Limited, Fresenius Kabi AG, Hetero Drugs Ltd, Eisai Co. Ltd, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Aspen Pharmacare Holdings Limited, Lupin Limited, Glenmark Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd, Medichem S.A., Centaur Pharmaceuticals Pvt. Ltd., Simson Pharma Limited, OPOCRIN SPA, Pinnacle Life Sciences Private Limited

https://www.thebusinessresearchcompany.com/report/apixaban-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Apixaban Industry?

North America was the largest region in the apixaban market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the apixaban market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=15979&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model